se of dried blood spots to measure methotrexate levels and its polyglutamates as biomarkers of methotrexate use in paediatric patients with Juvenile Idiopathic Arthritis (JIA) and Juvenile Dermatomyositis (JDM)
Not Applicable
Completed
- Conditions
- Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM)Musculoskeletal DiseasesJuvenile dermatomyositis
- Registration Number
- ISRCTN93945409
- Lead Sponsor
- Arthritis Research UK (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1. Children aged 4-16 years diagnosed with either juvenile idiopathic arthritis or juvenile dermatomyositis (confirmed by a consultant) attending the rheumatology clinic at the paediatric rheumatology outpatient clinics at three sites: the Royal Liverpool Children's Hospital (Liverpool), Musgrave Park Hospital (Belfast) and the University College London (UCL) Institute of Child Health / Great Ormond Street Hospital for Children (GOSH) (London)
2. The child is prescribed methotrexate for at least 2 months (oral or subcutaneous)
Exclusion Criteria
Do not meet the above inclusion criteria or if patients (or their parents/ guardians) do not wish to particpate in the research
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the possibility of developing an analytical method for the determination of methotrexate and its polyglutamate metabolites in dried blood spot samples
- Secondary Outcome Measures
Name Time Method To determine whether home sampling is practical